Tuesday, May 28, 2013

Investopedia: AstraZeneca Looks To Fish Oil To Round Out Its Cardio Portfolio

Investors waiting for M&A activity in the controversial purified pharma-grade fish oil market got some Tuesday morning, but probably not with the company they were expecting. AstraZeneca (NYSE:AZN) announced the acquisition of third-in-line pharma-grade fish oil company Omthera (Nasdaq:OMTH) for up to $443 million in total consideration. Although the deal offers a significant premium to where Omthera was trading and makes sense as a platform/portfolio addition, it's not exactly a risky high-value deal for AstraZeneca.

To read the full article, please click here:

No comments: